CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCD) FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS: INITIAL RESULTS OF A MULTICENTER, OPEN LABEL PHASE II STUDY

被引：0
|
作者：
Bringhen, S. [1 ]
Federica, C. [1 ]
Petrucci, M. [2 ]
Gay, F. [1 ]
Federico, V. [2 ]
Conticello, C. [2 ]
Pantani, L. [2 ]
Montefusco, V. [2 ]
Benevolo, G. [2 ]
Aschero, S. [1 ]
Offidani, M. [2 ]
Villani, O. [2 ]
Siniscalchi, A. [2 ]
Rossi, D. [2 ]
Magarotto, V. [1 ]
Sonneveld, P. [3 ]
Boccadoro, M. [1 ]
Palumbo, A. [1 ]
机构：
[1] Univ Torino, Div Hematol, Myeloma Unit, Turin, Italy
[2] GIMEMA, Italian Multiple Myeloma Network, Rome, Italy
[3] Erasmus MC, Dept Hematol, Rotterdam, Netherlands
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S578
引用
收藏
页码：242 / 242
页数：1
相关论文
共 50 条
  • [21] Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
    Mikhael, Joseph R.
    Reeder, Craig B.
    Libby, Edward N.
    Costa, Luciano J.
    Bergsagel, P. Leif
    Buadi, Francis
    Mayo, Angela
    Reddy, Sravan K. Nagi
    Gano, Katherine
    Dueck, Amylou C.
    Stewart, A. Keith
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (02) : 219 - 227
  • [22] A Multicenter Open Label Phase II Study of Pomalidomide, Cyclophosphamide and Dexamethasone in Relapse Multiple Myeloma Patients Initially Treated with Lenalidomide, Bortezomib and Dexamethasone
    Garderet, Laurent
    Kuhnowski, Frederique
    Mary, Jean Yves
    Roussel, Murielle
    Escoffre-Barbe, Martine
    Lafon, Ingrid
    Facon, Thierry
    Karlin, Lionel
    Perrot, Aurore
    Moreau, Philippe
    Marit, Gerald
    Stoppa, Anne-Marie
    Marolleau, Jean-Pierre
    Chaleteix, Carine
    Tiab, Mourad
    Araujo, Carla
    Lenain, Pascal
    Macro, Margaret
    Voog, Eric
    Benboubker, Lofti
    Allangba, Olivier
    Jourdan, Eric
    Mohty, Mohamad
    Loiseau, Herve Avet
    Mathiot, Claire
    Attal, Michel
    BLOOD, 2017, 130
  • [23] Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study
    Bringhen, Sara
    Oliva, Stefania
    Liberati, Anna Marina
    Belotti, Angelo
    Larocca, Alessandra
    Bonello, Francesca
    Gaidano, Gianluca
    Bertazzoni, Paola
    Esma, Fabrizio
    Stocchi, Raffaella
    Malfitano, Alessandra
    Ribolla, Rossella
    Di Sano, Chiara
    Aschero, Simona
    Patriarca, Francesca
    De Paoli, Lorenzo
    Cafro, Anna Maria
    Sonneveld, Pieter
    Palumbo, Antonio
    Boccadoro, Mario
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E59 - E59
  • [24] Induction Treatment With Cyclophosphamide, Thalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Phase II Study
    Yang, Deok-Hwan
    Kim, Yeo-Kyeoung
    Sohn, Sang-Kyun
    Chung, Joo-Seop
    Joo, Young-Don
    Lee, Jae-Hoon
    Lee, Jung-Lim
    Ahn, Jae-Sook
    Moon, Joon-Ho
    Shin, Ho-Jin
    Choi, Young-Jin
    Lee, Won-Sik
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (01): : 62 - 67
  • [25] An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma
    Nishihori, Taiga
    Baz, Rachid
    Shain, Kenneth
    Kim, Jongphil
    Ochoa-Bayona, Jose L.
    Yue, Binglin
    Sullivan, Daniel
    Dalton, William
    Alsina, Melissa
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (05) : 426 - 435
  • [26] AN OPEN-LABEL, PHASE 1B STUDY (MMY1001) OF DARATUMUMAB COMBINED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)
    Usmani, S. Z.
    Chari, A.
    Lonial, S.
    Weiss, B.
    Comenzo, R. L.
    Wu, K.
    Khokhar, N. Z.
    Wang, J.
    Doshi, P.
    Jakubowiak, A.
    HAEMATOLOGICA, 2017, 102 : 269 - 269
  • [27] Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
    S K Kumar
    I Flinn
    S J Noga
    P Hari
    R Rifkin
    N Callander
    M Bhandari
    J L Wolf
    C Gasparetto
    A Krishnan
    D Grosman
    J Glass
    E A Sahovic
    H Shi
    I J Webb
    P G Richardson
    S V Rajkumar
    Leukemia, 2010, 24 : 1350 - 1356
  • [28] Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
    Kumar, S. K.
    Flinn, I.
    Noga, S. J.
    Hari, P.
    Rifkin, R.
    Callander, N.
    Bhandari, M.
    Wolf, J. L.
    Gasparetto, C.
    Krishnan, A.
    Grosman, D.
    Glass, J.
    Sahovic, E. A.
    Shi, H.
    Webb, I. J.
    Richardson, P. G.
    Rajkumar, S. V.
    LEUKEMIA, 2010, 24 (07) : 1350 - 1356
  • [29] CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE (CTD) AS INITIAL THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Vasquez, J.
    Ruiz, R.
    Aliaga, K.
    Valencia, F.
    Enriquez, D.
    Palacios, V.
    Quintana, S.
    Casanova, L.
    HAEMATOLOGICA, 2016, 101 : 798 - 798
  • [30] Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II MultiCenter EVOLUTION Study
    Kumar, Shaji
    Flinn, Ian W.
    Noga, Stephen J.
    Hari, Parameswaran
    Rifkin, Robert M.
    Callander, Natalie Scott
    Bhandari, Manish
    Wolf, Jeffrey Lee
    Gasparetto, Cristina
    Krishnan, Amrita
    Grosman, Daren D.
    Glass, Jonathan
    Sahovic, Entezam Asim
    Shi, Hongliang
    Webb, Iain J.
    Richardson, Paul
    Rajkumar, S. Vincent
    BLOOD, 2008, 112 (11) : 41 - 42
12345